Cure8 news brief
This analysis suggests delivery method for the same anti‑TNF (infliximab) may affect long‑term clinical and endoscopic outcomes in ileal-predominant Crohn’s disease. If confirmed, route of maintenance dosing could influence treatment choices for a difficult‑to‑treat phenotype.
Gastroenterologists treating Crohn’s disease, patients on or considering infliximab maintenance (especially those with ileal-dominant disease), and researchers studying biologic delivery methods and biomarkers of response.
ACG meeting report: a pooled, propensity-matched analysis of registrational trials compared subcutaneous infliximab (Zymfentra) 120 mg Q2W with IV infliximab (Remicade) 5 mg/kg Q8W in patients with ileal or ileocolonic Crohn’s disease.
At week 54, subcutaneous maintenance showed higher rates of clinical remission and endoscopic response/remission versus IV maintenance in both unmatched and matched cohorts; subgroup analyses of isolated ileal disease suggested greater endoscopic benefit with subcutaneous delivery.
Serum infliximab concentrations were higher in endoscopic responders for both delivery routes. The report notes the need for larger prospective studies to confirm findings.
Results come from a pooled, post hoc analysis of registrational trials presented at a conference rather than a standalone randomized head‑to‑head trial. Authors call for additional prospective studies. Disclosures include investigator relationships with multiple industry sponsors.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...
